bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 535,630 shares, a growth of 142.0% from the February 26th total of 221,303 shares. Approximately 12.2% of the shares of the company are sold short. Based on an average daily volume of 25,841,541 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sabby Management LLC bought a new stake in bioAffinity Technologies during the 3rd quarter valued at $719,000. Scientech Research LLC purchased a new position in shares of bioAffinity Technologies in the third quarter valued at $49,000. Finally, Geode Capital Management LLC bought a new stake in shares of bioAffinity Technologies during the 4th quarter valued at $36,000. 1.64% of the stock is owned by institutional investors.

bioAffinity Technologies Price Performance

Shares of NASDAQ BIAF opened at $4.00 on Friday. The company has a current ratio of 2.60, a quick ratio of 2.58 and a debt-to-equity ratio of 0.08. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $2.21. bioAffinity Technologies has a 1-year low of $0.69 and a 1-year high of $46.53. The firm has a market cap of $18 million, a price-to-earnings ratio of -0.25 and a beta of 2.42.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings results on Saturday, March 14th. The company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($2.70) by $1.59. bioAffinity Technologies had a negative return on equity of 301.67% and a negative net margin of 241.93%.The company had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.55 million.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.